Search - tctmd.com

Displaying 201 - 220 of 433

Sort: Relevancy | Date

News Conference News AHA 2014

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

November 18, 2014

News Daily News

Immediate, Midterm Outcomes Encouraging for Bioresorbable Scaffolds in STEMI

Todd Neale

November 17, 2014

News Daily News

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

L.A. McKeown

November 02, 2014

Presentation TCT 2014

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Stephane Cook

September 16, 2014

Presentation TCT 2014

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Presenter: Marije L?wik

September 16, 2014

Presentation TCT 2014

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Presenter: Krishnankutty Sudhir

September 16, 2014

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

News Industry News

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

September 16, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

News Conference News TCT 2014

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

September 15, 2014

Presentation TCT 2014

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

Presenter: Donald Cutlip, Manel Sabate, Elvin Kedhi, Lisette Okkels Jensen

September 14, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2014

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

September 14, 2014

News Conference News TCT 2014

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

September 14, 2014

News Industry News

New Study Finds Everolimus-Eluting Stents Provide Superior Clinical Outcomes Compared to Drug-Eluting Balloons in Patients with Drug-Eluting Stent Restenosis

September 14, 2014

News Conference News TCT 2014

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

September 14, 2014

News Conference News TCT 2014

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

Yael L. Maxwell

September 14, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News ESC 2014

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Yael L. Maxwell

September 01, 2014

News Daily News

Similar Overall Long-Term Outcomes, Less Stent Thrombosis with Newer DES in STEMI

Todd Neale

August 22, 2014

Advertisement

Biodegradable-Polymer DES Perform Well But Appear No Safer than Their Durable-Polymer Counterparts

Immediate, Midterm Outcomes Encouraging for Bioresorbable Scaffolds in STEMI

TWENTE: Second-Generation DES Show Good Long-term Outcomes in Bifurcation Lesions

EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease

Comparison of Novel Zotarolimus-Eluting Cobalt-Chromium Stents and Everolimus-Eluting Platinum-Chromium Stents in Patients of the Randomized DUTCH PEERS Trial Presenting with___

Long-term Clinical Outcomes in Real-World Patients with Acute Myocardial Infarction Receiving XIENCE V® Everolimus-Eluting Stents: Four-Year Results from the XIENCE V USA Study_

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

Keynote Address Focuses on Newer DES, Problematic Subgroups

EES Decrease Restenosis, TVR vs. BMS in Non-STEMI

TCT 641: Improved Safety and Reduction in Stent Thrombosis After Everolimus-Eluting Stents Versus Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: SORT-OUT IV 5-Year Results

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

RIBS IV: EES Superior to DEB in Patients with In-Stent Restenosis

Pooled Trial Data Show No Stent Thrombosis Reduction with Biodegradable Stent

New Study Finds Everolimus-Eluting Stents Provide Superior Clinical Outcomes Compared to Drug-Eluting Balloons in Patients with Drug-Eluting Stent Restenosis

COMPARE II: STEMI Patients See Strong Results with Both BES and EES

ABSORB II: Similar Clinical Outcomes, Less Angina with Bioresorbable Scaffold vs. EES

COMPARE II: BES, EES Show Similar Outcomes at Three Years

BIOSCIENCE: Biodegradable Polymer SES Noninferior to Durable Polymer EES in All-Comers Trial

Similar Overall Long-Term Outcomes, Less Stent Thrombosis with Newer DES in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content